Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: Preclinical and Phase I trial results

PURPOSE: In this first-in-human, phase I, graft-versus-host disease (GVHD) prevention trial (NCT02891603) we combine pacritinib (PAC), a JAK2 inhibitor, with sirolimus to concurrently reduce T-cell costimulation via mTOR and IL-6 activity. We evaluate the safety of pacritinib when administered with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Pidala, Joseph, Walton, Kelly, Elmariah, Hany, Kim, Jongphil, Mishra, Asmita, Bejanyan, Nelli, Nishihori, Taiga, Khimani, Farhad, Perez, Lia, Faramand, Rawan G., Davila, Marco L., Nieder, Michael L., Sagatys, Elizabeth M., Holtan, Shernan G., Lawrence, Nicholas J., Lawrence, Harshani R., Blazar, Bruce R., Anasetti, Claudio, Sebti, Said M., Betts, Brian C.
Format: Artigo
Jezik:Inglês
Izdano: 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8127396/
https://ncbi.nlm.nih.gov/pubmed/33753457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4725
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items